- FDA advisory panel to consider OTC status of NSAIDs
- FDA advisory committees vote against changing naproxen label to highlight a lower CVD profile
- Study: Daily aspirin use may reduce risk of ovarian cancer by 20%
- Nuvo Research's Pennsaid 2% approved to treat pain associated with osteoarthritis of the knee
- FDA approves Iroko Pharmaceuticals NSAID
PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug for arthritis made by Watson Pharmaceuticals, the company said.
Watson announced that the FDA approved a subsidiary's application for diclofenac sodium and misoprostol delayed-release tablets. The drug is a generic version of G.D. Searle's Arthrotec, used to treat osteoarthritis and rheumatoid arthritis in patients who have high risk of developing ulcers related to the use of non-steroidal anti-inflammatory drugs, or NSAIDs, a class that includes the painkiller ibuprofen.
Arthrotec had sales of about $130 million during the 12-month period ended in May, according to IMS Health data.